Pharmacokinetics and toxicity of subcutaneous administration of carboplatin in poloxamer 407 in a rodent model pilot study

Public Deposited
Analytics

Downloadable Content

Download PDF
Request Version for Screen Reader
Creator
  • Risselada, Marije
    • Other Affiliation: Department of Veterinary Clinical Sciences; College of Veterinary Medicine; Purdue University
  • Linder, Keith E.
    • Other Affiliation: Department of Population Health and Pathobiology; College of Veterinary Medicine; North Carolina State University
  • Griffith, Emily
    • Other Affiliation: Department of Clinical Sciences; College of Veterinary Medicine; North Carolina State University
  • Roberts, Brittney V.
    • Affiliation: Eshelman School of Pharmacy
  • Davidson, Gigi
    • Other Affiliation: CPS; College of Veterinary Medicine; North Carolina State University
  • Zamboni, William C.
    • Affiliation: Eshelman School of Pharmacy
  • Messenger, Kristen M.
    • Other Affiliation: Department of Molecular Biomedical Sciences; College of Veterinary Medicine; North Carolina State University
Abstract
  • The objectives of this study were to assess the pharmacokinetics and safety of subcutaneously delivered carboplatin in poloxamer 407 in rats. Carboplatin (5mg/rat) in 0.5ml poloxamer 407 (1.0 ml total volume) was administered subcutaneously in a right subcutaneous perineal incision in all 12 treatment rats. Three control rats received 1.0 ml of poloxamer 407. Total platinum was measured in plasma q24hrs from 0 to 168hrs. Protein-unbound platinum was measured in plasma at 168hrs. After sacrifice on day 7, total platinum was determined in wound bed muscle. Platinum concentrations in all samples were measured by ICP-MS. Wounds were visually assessed daily for 7 days. Perineal tissues (full wound bed including muscle, subcutis, skin) were assessed histologically and scored. Total platinum was detectable in plasma from 24 to 168 hrs. Total plasma platinum AUC and Cmax were 9,165.3 ng/mL•h and 129.4 ng/mL. Day 7 total platinum concentration in muscle was approximately 10-fold higher than total plasma platinum concentration. No unbound platinum was detected in plasma samples at 168 hours. No wound healing complications were detected at any time point, nor was tissue necrosis observed histologically. The results of this study suggest that subcutaneous carboplatin in poloxamer 407 can be used in vivo providing direct tissue exposure to carboplatin without significant local effects or systemic absorption and without wound healing complications.
Date of publication
Keyword
DOI
Identifier
Resource type
  • Article
Rights statement
  • In Copyright
Journal title
  • PloS One
Journal volume
  • 12
Journal issue
  • 10
Page start
  • e0186018
Language
  • English
ISSN
  • 1932-6203

Relations

Parents:

This work has no parents.

In Collection:

Items

Thumbnail Title Date Uploaded Visibility Actions
file details PubMedCentral-PMC5642013.pdf 2017 Public Download